NewAmsterdam Pharma [NAMSW] vs Invivyd [IVVD] Detailed Stock Comparison
NewAmsterdam Pharma
NASDAQ
Loading...
Invivyd
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: NewAmsterdam Pharma wins in 10 metrics, Invivyd wins in 4 metrics, with 0 ties. NewAmsterdam Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | NewAmsterdam Pharma | Invivyd | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | -0.81 | N/A |
| Price-to-Book Ratio | 2.75 | 3.26 | NewAmsterdam Pharma |
| Debt-to-Equity Ratio | 0.04 | 6.93 | NewAmsterdam Pharma |
| PEG Ratio | N/A | 0.01 | N/A |
| EV/EBITDA | 4.84 | -0.96 | Invivyd |
| Profit Margin (TTM) | -258.91% | -238.33% | Invivyd |
| Operating Margin (TTM) | -186.13% | -127.78% | Invivyd |
| Return on Equity | -28.43% | -120.08% | NewAmsterdam Pharma |
| Return on Assets (TTM) | -17.12% | -53.25% | NewAmsterdam Pharma |
| Free Cash Flow (TTM) | $-159.24M | $-170.63M | NewAmsterdam Pharma |
| 1-Year Return | 151.52% | 39.22% | NewAmsterdam Pharma |
| Price-to-Sales Ratio (TTM) | 0.00 | 5.38 | NewAmsterdam Pharma |
| Enterprise Value | $-771.30M | $107.43M | Invivyd |
| EV/Revenue Ratio | -16.93 | 2.33 | NewAmsterdam Pharma |
| Gross Profit Margin (TTM) | N/A | 94.19% | N/A |
| Revenue per Share (TTM) | $1 | $0 | NewAmsterdam Pharma |
| Earnings per Share (Diluted) | N/A | $-0.92 | N/A |
| Beta (Stock Volatility) | 0.03 | 0.57 | NewAmsterdam Pharma |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
NewAmsterdam Pharma vs Invivyd Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| NewAmsterdam Pharma | 9.10% | 17.23% | 53.48% | 125.30% | 245.26% | 44.20% |
| Invivyd | 22.41% | 26.79% | 22.41% | 102.86% | 178.43% | 195.83% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| NewAmsterdam Pharma | 151.52% | 2,864.29% | 790.56% | 790.56% | 790.56% | 790.56% |
| Invivyd | 39.22% | -56.71% | -93.20% | -93.20% | -93.20% | -93.20% |
News Based Sentiment: NewAmsterdam Pharma vs Invivyd
NewAmsterdam Pharma
News based Sentiment: MIXED
The month saw a mix of positive developments – increased investor interest and upcoming data presentations – alongside insider selling, creating a mixed outlook for the company. The presentations at medical and investor conferences are key catalysts, but the insider sales introduce a note of caution.
Invivyd
News based Sentiment: MIXED
Invivyd experienced a mixed month with disappointing earnings and a stock decline, countered by a significant securities filing to secure funding and positive clinical trial data. The diverging analyst ratings and high stock volatility create a complex investment picture, making this a noteworthy but risky situation for investors.
Performance & Financial Health Analysis: NewAmsterdam Pharma vs Invivyd
| Metric | NAMSW | IVVD |
|---|---|---|
| Market Information | ||
| Market Cap | $0 | $247.29M |
| Market Cap Category | Micro cap | Micro cap |
| 10 Day Avg. Volume | 5,970 | 1,965,230 |
| 90 Day Avg. Volume | 3,883 | 10,635,607 |
| Last Close | $20.75 | $1.42 |
| 52 Week Range | $5.45 - $22.00 | $0.35 - $2.74 |
| % from 52W High | -5.68% | -48.18% |
| All-Time High | $22.00 (Oct 06, 2025) | $78.82 (Nov 29, 2021) |
| % from All-Time High | -5.68% | -98.20% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 7.40% | 4.21% |
| Quarterly Earnings Growth | 7.40% | 4.21% |
| Financial Health | ||
| Profit Margin (TTM) | -2.59% | -2.38% |
| Operating Margin (TTM) | -1.86% | -1.28% |
| Return on Equity (TTM) | -0.28% | -1.20% |
| Debt to Equity (MRQ) | 0.04 | 6.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.92 | $0.36 |
| Cash per Share (MRQ) | $6.56 | $0.29 |
| Operating Cash Flow (TTM) | $-124,122,000 | $-113,108,000 |
| Levered Free Cash Flow (TTM) | $-85,028,000 | $-47,749,248 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: NewAmsterdam Pharma vs Invivyd
| Metric | NAMSW | IVVD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | -0.81 |
| Forward P/E | N/A | -5.80 |
| PEG Ratio | N/A | 0.01 |
| Price to Sales (TTM) | 0.00 | 5.38 |
| Price to Book (MRQ) | 2.75 | 3.26 |
| Market Capitalization | ||
| Market Capitalization | $0 | $247.29M |
| Enterprise Value | $-771,295,000 | $107.43M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -16.93 | 2.33 |
| Enterprise to EBITDA | 4.84 | -0.96 |
| Risk & Other Metrics | ||
| Beta | 0.03 | 0.57 |
| Book Value per Share (MRQ) | $6.92 | $0.36 |
Financial Statements Comparison: NewAmsterdam Pharma vs Invivyd
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NAMSW | IVVD |
|---|---|---|
| Revenue/Sales | $2.98M | $11.79M |
| Cost of Goods Sold | N/A | $685,000 |
| Gross Profit | N/A | $11.10M |
| Research & Development | $44.75M | $9.57M |
| Operating Income (EBIT) | $-68.93M | $-15.06M |
| EBITDA | $-90.92M | $-14.56M |
| Pre-Tax Income | $-39.53M | $-14.66M |
| Income Tax | $0 | N/A |
| Net Income (Profit) | $-39.53M | $-14.66M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NAMSW | IVVD |
|---|---|---|
| Cash & Equivalents | $748.42M | $48.08M |
| Total Current Assets | $817.30M | $75.83M |
| Total Current Liabilities | $40.91M | $49.60M |
| Long-Term Debt | $137,000 | N/A |
| Total Shareholders Equity | $777.36M | $54.15M |
| Retained Earnings | $-598.10M | $-918.28M |
| Property, Plant & Equipment | $607,000 | $2.48M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NAMSW | IVVD |
|---|---|---|
| Operating Cash Flow | $-24.99M | $-12.47M |
| Capital Expenditures | $-16,000 | $-144,000 |
| Free Cash Flow | $-36.48M | $-21.27M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NAMSW | IVVD |
|---|---|---|
| Shares Short | N/A | 7.26M |
| Short Ratio | N/A | 0.50 |
| Short % of Float | N/A | 0.05% |
| Average Daily Volume (10 Day) | 5,970 | 1,965,230 |
| Average Daily Volume (90 Day) | 3,883 | 10,635,607 |
| Shares Outstanding | 108.06M | 119.84M |
| Float Shares | 56.14M | 72.18M |
| % Held by Insiders | N/A | 0.19% |
| % Held by Institutions | N/A | 0.61% |
Dividend Analysis & Yield Comparison: NewAmsterdam Pharma vs Invivyd
| Metric | NAMSW | IVVD |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |